Pulmatrix GAAP EPS of -$0.34

Pulmatrix reported a GAAP EPS of -$0.34 for Q3 2026. The company released this financial update in a press statement.

Original reporting
Published Nov 17, 2026, 1:25 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 1:29 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$PULM
Bearish
medium confidence
Mentioned
$PULM
Relevance
6/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$PULMBearishMed
01

Why it matters

A reported GAAP EPS loss is a direct earnings signal, but the excerpt provides no guidance, revenue, or balance-sheet context to refine expectations.

02

Market read

This is a company-specific earnings datapoint that can drive near-term positioning, but the excerpt lacks the usual decision-critical details (guidance, revenue, cash).

03

What to watch

Traders will likely focus on revenue trend, cash runway, R&D spend, and any forward guidance, none of which are included in the provided text.

Relevance 6/10Novelty 6/10Timing: reported in the morning (Nov 17, 2026) ahead of the trading day

Background

The piece is a Seeking Alpha earnings news blurb referencing Pulmatrix’s Q3 GAAP EPS press release.

Company-level read

Ticker impact

$PULMBearishMedium confidence
Context

Article states Pulmatrix reported Q3 GAAP EPS of -$0.34 in its press release, a direct earnings datapoint for PULM.

Expected impact

Likely downward or volatile reaction as the market prices ongoing losses and seeks clearer path to profitability.

Evidence & confidence

The only disclosed figure is a negative GAAP EPS for Q3; without revenue, guidance, or balance-sheet details, the most defensible read-through is continued loss-making.

Market effects

Limited spillover; single-company biotech/clinical-stage earnings datapoint with no sector-wide catalyst described.

No specific regional macro or cross-market linkage mentioned.

No global linkage beyond the company’s own earnings print.

Counterpoint

If the market was already expecting worse losses, the -$0.34 GAAP EPS could be less negative than feared, limiting downside.

Key entities

  • Pulmatrix, Inc.

    Subject of the article, reporting Q3 GAAP EPS of -$0.34.

Related articles

$PULMMed

Pulmatrix Announces Third Quarter 2026 Financial Results and Progress on Merger

Pulmatrix, Inc. (PULM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Pulmatrix Announces Third Quarter 2026 Financial Results and Progress on Merger Merger with Eos SENOLYTIX expected to close by end of the year Framingham, Mass., November 17, 2026 – Pulmatrix, Inc. (“Pulmatrix”, the “Company” or “our”) (Nasdaq: PULM), a biopharmaceut

$PULMMedAI 8/10

Eos reports early rat study data for aging drug candidate

Eos SENOLYTIX reported interim data from a rat study of its aging drug candidate PTC-2105, showing improved motor performance and reduced fat mass. The 32-week study involves 268 rats, with the oldest cohort showing positive results. Eos plans FDA submission and human trials in 2027. The company is merging with Pulmatrix Inc. (PULM), expected to close in Q4 2026.

$PULMMed

Pulmatrix Announces Second Quarter 2026 Financial Results and Progress on Merger

Pulmatrix, Inc. (PULM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Pulmatrix Announces Second Quarter 2026 Financial Results and Progress on Merger Form S-4 filed related to the announced merger agreement with Eos SENOLYTIX Framingham, Mass., August 13, 2026 – Pulmatrix, Inc. (“Pulmatrix” or the “Company”) (Nasdaq: PULM), a biopharm